IL6 and breast carcinoma: It was previously reported in a clinical trial that breast cancer patients may enjoy a good prognosis by reducing the serum levels of inflammatory factors IL-6, IL-8, and TNF-α, and this might even offer protection from the metastases and recurrence of breast cancer (38).